<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30390563</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN><JournalIssue CitedMedium="Internet"><Volume>526</Volume><PubDate><Year>2019</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>154</EndPage><MedlinePgn>146-154</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2018.10.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0042-6822(18)30326-X</ELocationID><Abstract><AbstractText>Enterovirus D68 (EV-D68) is unique among enteroviruses because of the ability to cause severe respiratory disease as well as neurological disease. We developed separate models of respiratory and neurological disease following EV-D68 infection in AG129 mice that respond to antiviral treatment with guanidine. In four-week-old mice infected intranasally, EV-D68 replicates to high titers in lung tissue increasing the proinflammatory cytokines MCP-1 and IL-6. The respiratory infection also produces an acute viremia. In 10-day-old mice infected intraperitoneally, EV-D68 causes a neurological disease with weight-loss, paralysis, and mortality. In our respiratory model, treatment with guanidine provides a two-log reduction in lung virus titers, reduces MCP-1 and IL-6, and prevents histological lesions in the lungs. Importantly, viremia is prevented by early treatment with guanidine. In our neurological model, guanidine treatment protects mice from weight-loss, paralysis, and mortality. These results demonstrate the utility of these models for evaluation of antiviral therapies for EV-D68 infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>Brett L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, United States; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>W Joseph</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, United States; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smee</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, United States; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wettere</LastName><ForeName>Arnaud J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, United States; Utah Veterinary Diagnostic Laboratory, Logan, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarbet</LastName><ForeName>E Bart</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT, United States; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, United States; Utah Veterinary Diagnostic Laboratory, Logan, UT, United States. Electronic address: bart.tarbet@usu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201000039I</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU58VJ6Y3B</RegistryNumber><NameOfSubstance UI="D019791">Guanidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019791" MajorTopicYN="N">Guanidine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute flaccid myelitis</Keyword><Keyword MajorTopicYN="N">Animal model</Keyword><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Enterovirus D68</Keyword><Keyword MajorTopicYN="N">Guanidine</Keyword><Keyword MajorTopicYN="N">Neurological disease</Keyword><Keyword MajorTopicYN="N">Respiratory disease</Keyword></KeywordList><CoiStatement>Conflicts of Interest. The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30390563</ArticleId><ArticleId IdType="mid">NIHMS1511431</ArticleId><ArticleId IdType="pmc">PMC6309259</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2018.10.014</ArticleId><ArticleId IdType="pii">S0042-6822(18)30326-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Imamura T, Oshitani H. 2015. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol 25:102&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407910</ArticleId><ArticleId IdType="pubmed">25471236</ArticleId></ArticleIdList></Reference><Reference><Citation>Control CfD. July 19, 2016
2017. 
Enterovirus D68. https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html.
Accessed
5/22/2017.</Citation></Reference><Reference><Citation>Messacar K, Abzug MJ, Dominguez SR. 2016. 2014 outbreak of enterovirus D68 in North America. J Med Virol 88:739&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">26489019</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Hawkins SM, Baker J, Pearce K, Tong S, Dominguez SR, Parker S. 2016. Resource Burden During the 2014 Enterovirus D68 Respiratory Disease Outbreak at Children&#x2019;s Hospital Colorado: An Unexpected Strain. JAMA Pediatr 170:294&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26783716</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence NV. 2015. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol 36:245&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965662</ArticleId><ArticleId IdType="pubmed">25414005</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, Nix WA, Robinson CC, Glode MP, Abzug MJ, Dominguez SR. 2015. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 385:1662&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">25638662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea C, Bitnun A, Robinson J, Mineyko A, Barton M, Mah JK, Vajsar J, Richardson S, Licht C, Brophy J, Crone M, Desai S, Hukin J, Jones K, Muir K, Pernica JM, Pless R, Pohl D, Rafay MF, Selby K, Venkateswaran S, Bernard G, Yeh EA. 2017. Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. J Child Neurol 32:301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">28193112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangermann RH, Lamoureux C, Tallis G, Goel A. 2017. The critical role of acute flaccid paralysis surveillance in the Global Polio Eradication Initiative. Int Health 9:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">28582560</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Department of Vaccines and Other Biologicals. 2003. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Dept. of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva.</Citation></Reference><Reference><Citation>Nelson GR, Bonkowsky JL, Doll E, Green M, Hedlund GL, Moore KR, Bale JF Jr. 2016. Recognition and Management of Acute Flaccid Myelitis in Children. Pediatr Neurol 55:17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26621554</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E, Sejvar JJ, Nix WA, Oberste MS, Feikin DR, Dominguez SR. 2016. Enterovirus D68 Infection in Children with Acute Flaccid Myelitis, Colorado, USA, 2014. Emerg Infect Dis 22:1387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982171</ArticleId><ArticleId IdType="pubmed">27434186</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Bosis S, Niesters H, Principi N. 2015. Enterovirus D68 Infection. Viruses 7:6043&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664996</ArticleId><ArticleId IdType="pubmed">26610548</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Chidini G, Cinnante C, Napolitano L, Giannini A, Terranova L, Niesters H, Principi N, Calderini E. 2017. Acute flaccid myelitis associated with enterovirus-D68 infection in an otherwise healthy child. Virol J 14:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234096</ArticleId><ArticleId IdType="pubmed">28081720</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012&#x2013;14): a retrospective cohort study. Lancet Infect Dis 15:671&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027625</ArticleId><ArticleId IdType="pubmed">25837569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovden IA, Pfeiffer HC. 2015. Electrodiagnostic findings in acute flaccid myelitis related to enterovirus D68. Muscle Nerve 52:909&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26082087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang M, Mirand A, Savy N, Henquell C, Maridet S, Perignon R, Labbe A, Peigue-Lafeuille H. 2014. Acute flaccid paralysis following enterovirus D68 associated pneumonia, France, 2014. Euro Surveill 19.</Citation><ArticleIdList><ArticleId IdType="pubmed">25394254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Peigue-Lafeuille H. 2015. Acute flaccid myelitis and enteroviruses: an ongoing story. Lancet 385:1601&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">25638661</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer HC, Bragstad K, Skram MK, Dahl H, Knudsen PK, Chawla MS, Holberg-Petersen M, Vainio K, Dudman SG, Kran AM, Rojahn AE. 2015. Two cases of acute severe flaccid myelitis associated with enterovirus D68 infection in children, Norway, autumn 2014. Euro Surveill 20:21062.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Crone M, Tellier R, Wei XC, Kuhn S, Vanderkooi OG, Kim J, Mah JK, Mineyko A. 2016. Polio-Like Illness Associated With Outbreak of Upper Respiratory Tract Infection in Children. J Child Neurol 31:409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">26215391</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Iyer A, Hunter K, Cargill JS, Cooke RP. 2015. Sampling the upper respiratory tract for enteroviral infection is important in the investigation of an acute neurological illness in children. Eur J Paediatr Neurol 19:494&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25868937</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ, Thomas RH, Pickersgill TP, Lyons M, Lowe G, Stiff RE, Moore C, Jones R, Howe R, Brunt H, Ashman A, Mason BW. 2016. Cluster of atypical adult Guillain-Barre syndrome temporally associated with neurological illness due to EV-D68 in children, South Wales, United Kingdom, October 2015 to January 2016. Euro Surveill 21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26848143</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8009221</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol 69:4792&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189290</ArticleId><ArticleId IdType="pubmed">7609046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Yu G, Leser JS, Yagi S, Clarke P, Chiu CY, Tyler KL. 2017. A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog 13:e1006199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322875</ArticleId><ArticleId IdType="pubmed">28231269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowen BB, Wong MH, Larson D, Ye W, Jung KH, Sefing EJ, Skirpstunas R, Smee DF, Morrey JD, Schneller SW. 2&#x2013;10. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.. PLoS One. 5(9). pii: e12760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940843</ArticleId><ArticleId IdType="pubmed">20862280</ArticleId></ArticleIdList></Reference><Reference><Citation>Julander JG, Perry ST, Shresta S. 2011. Important advances in the field of anti-dengue virus research. Antivir Chem Chemother. 21(3):105&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">21233532</ArticleId></ArticleIdList></Reference><Reference><Citation>Julander JG, Siddharthan VJ. 2017. Small-Animal Models of Zika Virus. Infect Dis. 216(suppl_10):S919&#x2013;S927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853237</ArticleId><ArticleId IdType="pubmed">29267919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarathy VV, Milligan GN, Bourne N, Barrett AD. 2015. Mouse models of dengue virus infection for vaccine testing. Vaccine. 33(50):7051&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563257</ArticleId><ArticleId IdType="pubmed">26478201</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Li L, Lei X, Zhou H, Zhou Z, He B, Wang J. 2014. Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3. J Virol 88:6650&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054379</ArticleId><ArticleId IdType="pubmed">24672048</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Liu L, Lei X, Zhou Z, He B, Wang J. 2015. 3C Protease of Enterovirus D68 Inhibits Cellular Defense Mediated by Interferon Regulatory Factor 7. J Virol 90:1613&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719596</ArticleId><ArticleId IdType="pubmed">26608321</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Su J, Wang H, Chang J, Wang S, Zheng W, Cai Y, Wei W, Gordy JT, Markham R, Kong W, Zhang W, Yu XF. 2017. Disruption of MDA5-Mediated Innate Immune Responses by the 3C Proteins of Coxsackievirus A16, Coxsackievirus A6, and Enterovirus D68. J Virol 91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469270</ArticleId><ArticleId IdType="pubmed">28424289</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans WJ, Hurst BL, Peterson CJ, Van Wettere A, Day CW, Smee DF, and Tarbet EB Development of a Respiratory Disease Model for Enterovirus D68 in 4-Week-Old Mice for Evaluation of Antiviral Therapies. (manuscript submitted).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997929</ArticleId><ArticleId IdType="pubmed">30521834</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. 2016. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res 131:61&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LM H 1938. A Simple Method of Estimating Fifty Percent Endpoints. The American Journal of Hygiene 27:493&#x2013;497.</Citation></Reference><Reference><Citation>Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG. 2015. A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. J Vis Exp doi:10.3791/53257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53257</ArticleId><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council (U.S.) Committe for the Update of the Guide for the Care and Use of Laboratory Animals IfLARUS, National Academies Press (U.S.) 2011. Guide for the care and use of Laboratory Animals National Academies Press,</Citation><ArticleIdList><ArticleId IdType="pubmed">21595115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Clarke P, Tyler KL. 2017. Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis. J Infect Dis 216:1245&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853295</ArticleId><ArticleId IdType="pubmed">28968718</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliguiri LA, Tamm I. 1968. Action of guanidine on the replication of poliovirus RNA. Virology 35:408&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">4298649</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). 2011. Clusters of acute respiratory illness associated with human enterovirus 68&#x2014;Asia, Europe, and United States, 2008&#x2013;2010. MMWR Morb Mortal Wkly Rep;60:1301&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">21956405</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Nix WA, Watson JT, Gerber SI. 2014. Severe respiratory illness associated with enterovirus D68&#x2014; Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep; 63:798&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584696</ArticleId><ArticleId IdType="pubmed">25211545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs SE, Soave R, Shore TB, Satlin MJ, Schuetz AN, Magro C, Jenkins SG, Walsh TJ. 2013. Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients. Transpl Infect Dis 15:474&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962254</ArticleId><ArticleId IdType="pubmed">23890179</ArticleId></ArticleIdList></Reference><Reference><Citation>Imakita M, Shiraki K, Yutani C, Ishibashi-Ueda H. 2000. Pneumonia caused by rhinovirus. Clin Infect Dis 30:611&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722460</ArticleId></ArticleIdList></Reference><Reference><Citation>Banna GL, Aversa SM, Cattelan AM, Crivellari G, Monfardini S. 2004. Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. Scand J Infect Dis 36:155&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15061675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibino M, Kondo T. 2017. Interstitial Pneumonia Associated with the Influenza Vaccine: A Report of Two Cases. Intern Med 56:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337467</ArticleId><ArticleId IdType="pubmed">28090052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomask M 2006. Further exploration of the Penh parameter. Exp Toxicol Pathol 57 Suppl 2:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16638630</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachery VD, Gralinski LE, Baric RS, Ferris MT. 2015. New Metrics for Evaluating Viral Respiratory Pathogenesis. PLoS One 10:e0131451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482571</ArticleId><ArticleId IdType="pubmed">26115403</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundblad LK, Irvin CG, Hantos Z, Sly P, Mitzner W, Bates JH. 2007. Penh is not a measure of airway resistance! Eur Respir J 30:805.</Citation><ArticleIdList><ArticleId IdType="pubmed">17906089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates J, Irvin C, Brusasco V, Drazen J, Fredberg J, Loring S, Eidelman D, Ludwig M, Macklem P, Martin J, Milic-Emili J, Hantos Z, Hyatt R, Lai-Fook S, Leff A, Solway J, Lutchen K, Suki B, Mitzner W, Pare P, Pride N, Sly P. 2004. The use and misuse of Penh in animal models of lung disease. Am J Respir Cell Mol Biol 31:373&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15317683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">4340949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidwell RW, Hitchcock M, Okleberry KM, Burger RA, Warren RP, Morrey JD. 1992. Suppression of murine retroviral disease by 2&#x2019;,3&#x2019;-didehydro-2&#x2019;,3&#x2019;-dideoxythymidine (D4T). Antiviral Res 19:313&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334395</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T, Kim CU. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37:107&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9588843</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45:743&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC90367</ArticleId><ArticleId IdType="pubmed">11181354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1803113</ArticleId><ArticleId IdType="pubmed">17194832</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson CJ, Hurst BL, Evans WJ, Smee DF, and Tarbet EB Evaluation of human intravenous immunoglobulin in disease models of EV-D68 and EV-71 infections in mice. (manuscript submitted).</Citation></Reference><Reference><Citation>Morrey JD, Wang H, Hurst BL, Zukor K, Siddharthan V, Van Wettere AJ, Sinex DG, Tarbet EB. 2018. Causation of Acute Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 Infected Mice Deficient in Interferon alphabeta/gamma Receptors. Viruses 10(1). pii: E33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5795446</ArticleId><ArticleId IdType="pubmed">29329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert EH. 1966. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci 135:367&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">5221351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist S, Stangel M. 2011. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 7:341&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148925</ArticleId><ArticleId IdType="pubmed">21822385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. 2012. Selection and characterisation of guanidine-resistant mutants of human enterovirus 71. Virus Res 169:72&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22814431</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers HJ. 1976. Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. J Exp Med 143:1367&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190224</ArticleId><ArticleId IdType="pubmed">1271013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>